Madeleine N Stevens Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 301 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-385-5281 |
Teambuilders Behavioral Health, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 301 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-867-2383 Fax: 505-867-7293 |
La Buena Vida, Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 872 Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-867-2383 Fax: 505-867-7293 |
Valle Del Sol Of New Mexico, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 282 S Camino Del Pueblo, Suite 2c, Bernalillo, NM 87004 Phone: 602-258-6797 Fax: 602-248-8113 |
Five Sandoval Indian Pueblos, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 1043 Hwy 313, Bernalillo, NM 87004 Phone: 505-867-3351 Fax: 505-867-3514 |
Bernalillo Public Schools (bps) Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 560 S Camino Del Pueblo, Bernalillo, NM 87004 Phone: 505-404-5716 |
News Archive
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
Altarum Institute has received an award of $8.4 million from the Center for Medicare and Medicaid Innovation (CMMI) to curb unnecessary medical imaging in Southeast Michigan.
Earlier studies have pegged the risk of motor vehicle crashes with teenagers suffering from attention-deficit hyperactivity disorder (ADHD) behind the wheel, as much higher than what a recent study has revealed. Now it is known that the risk of a motor vehicle crashes with adolescents with ADHD is 36% higher than all other newly licensed teenagers and young drivers. This is high but earlier the risk was considered to be four times higher than this.
Sermo, the world's largest online community for physicians, today announced a Sermo Eventâ„¢ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.
A new device could help to relieve the pain and discomfort experienced by thousands of amputees as a result of poorly fitting replacement lower limbs. Researchers are developing a prototype of the world's first prosthetic 'intelligent' liner with integrated pressure sensors, which could be available to NHS patients in as little as three years.
› Verified 2 days ago